A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na ïve Metastatic Prostate Cancer.

CONCLUSIONS: Cabozantinib plus ADT has promising clinical activity in HNMPCa. CAF profiles and tissue markers suggest candidate prognostic and predictive markers of cabozantinib benefit and provide insights for rational therapy combinations.
PMID: 31941830 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 14, 2020 Category: Cancer & Oncology Authors: Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C Tags: Clin Cancer Res Source Type: research